NCT04800822: PF-07284892 in Participants With Advanced Solid Tumors |
|
|
| Terminated | 1 | 53 | US | PF-07284892, ARRY-558, lorlatinib, Lorbrena; PF-06463922, Lorviqua, binimetinib, Mektovi, PF-06811462, MEK162, cetuximab, Erbitux, encorafenib, Braftovi, PF-07263896, LGX818 | Pfizer | Solid Tumor | 06/24 | 06/24 | | |
NCT06704724: A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene |
|
|
| Not yet recruiting | 1 | 230 | NA | PF-07985045, PF-5045, Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, Cetuximab, Erbitux, Fluorouracil, 5-FU, 5-fluorouracil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium, Bevacizumab, Zirabev, Avastin, Pembrolizumab, Pembro, Lambrolizumab, MK-3475, Keytruda, Sasanlimab, PF-06801591, pemetrexed, Alimta, Cisplatin, Platinol, Cisplatinum, neoplatin, Paclitaxel, Taxol, Onxol, Carboplatin, Paraplatin, Stricarb, PF-07284892, ARRY-558 | Pfizer | Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | 01/28 | 01/29 | | |
